CHF 1535 clinical trials
Also written CHF1535.
How each study uses CHF 1535 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CHF 1535 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPDCompletedPhase 4Chiesi Farmaceutici S.p.A.NCT05097014Written as CHF1535
- BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)CompletedPhase 3Chiesi Farmaceutici S.p.A.NCT00929851Written as CHF1535
- Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD PatientsCompletedPhase 1/2Chiesi Farmaceutici S.p.A.NCT01176747Written as BDP/formoterol NEXT DPI
- A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01191424Written as CHF1535 NEXT DPI
- A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT03108534Written as CHF1535 NEXThaler
- Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic PatientsCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT00868023Written as CHF 1535 Next DPI
- Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic ChildrenCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT01475032Written as CHF 1535
As the comparator · 2 — what is tested is compared with CHF 1535
- Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPDCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01584505Written as CHF1535 daily dose
- Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT03590379Written as CHF 1535 pMDI